MARKET

NCNA

NCNA

Nucana
NASDAQ
3.570
-0.130
-3.51%
Opening 13:43 01/06 EST
OPEN
3.660
PREV CLOSE
3.700
HIGH
3.730
LOW
3.500
VOLUME
61.90K
TURNOVER
--
52 WEEK HIGH
273.92
52 WEEK LOW
2.780
MARKET CAP
25.60M
P/E (TTM)
-0.0005
1D
5D
1M
3M
1Y
5Y
1D
NuCana appoints Theresa Bruce as chief operating officer
Seeking Alpha · 5h ago
NuCana Names Theresa Bruce Chief Operating Officer to Drive Oncology Pipeline
TipRanks · 5h ago
NuCana Appoints Theresa Bruce COO, Effective Jan. 1
Benzinga · 6h ago
NuCana Appoints Theresa Bruce as Chief Operating Officer
Reuters · 6h ago
Weekly Report: what happened at NCNA last week (1229-0102)?
Weekly Report · 1d ago
Weekly Report: what happened at NCNA last week (1222-1226)?
Weekly Report · 12/29/2025 09:57
Weekly Report: what happened at NCNA last week (1215-1219)?
Weekly Report · 12/22/2025 09:57
BRIEF-NuCana Reinstates Hugh Griffith as CEO and Chief Executive Officer
Reuters · 12/17/2025 14:18
More
About NCNA
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Webull offers NuCana PLC (ADR) stock information, including NASDAQ: NCNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NCNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NCNA stock methods without spending real money on the virtual paper trading platform.